A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo T. Stühmer et.al. ASCO Annual Meeting 2008;Vol 26, No 15S
HDM2 antagonist JNJ-26854165 http://www.cancer.gov/drugdictionary/?CdrID=596734
The pharmacological and toxicological properties of this product have not been fully investigated. Exercise caution in use and handling. This product must not be used in humans.